108 related articles for article (PubMed ID: 36065524)
41. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.
Lenz HJ; Van Cutsem E; Luisa Limon M; Wong KYM; Hendlisz A; Aglietta M; García-Alfonso P; Neyns B; Luppi G; Cardin DB; Dragovich T; Shah U; Abdullaev S; Gricar J; Ledeine JM; Overman MJ; Lonardi S
J Clin Oncol; 2022 Jan; 40(2):161-170. PubMed ID: 34637336
[TBL] [Abstract][Full Text] [Related]
42. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.
Blank CU; Rozeman EA; Fanchi LF; Sikorska K; van de Wiel B; Kvistborg P; Krijgsman O; van den Braber M; Philips D; Broeks A; van Thienen JV; Mallo HA; Adriaansz S; Ter Meulen S; Pronk LM; Grijpink-Ongering LG; Bruining A; Gittelman RM; Warren S; van Tinteren H; Peeper DS; Haanen JBAG; van Akkooi ACJ; Schumacher TN
Nat Med; 2018 Nov; 24(11):1655-1661. PubMed ID: 30297911
[TBL] [Abstract][Full Text] [Related]
43. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
Tan I; Malinzak M; Salama AKS
J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
[TBL] [Abstract][Full Text] [Related]
44. Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study.
Pelster MS; Gruschkus SK; Bassett R; Gombos DS; Shephard M; Posada L; Glover MS; Simien R; Diab A; Hwu P; Carter BW; Patel SP
J Clin Oncol; 2021 Feb; 39(6):599-607. PubMed ID: 33125309
[TBL] [Abstract][Full Text] [Related]
45. Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204).
Tawbi HA; Forsyth PA; Hodi FS; Lao CD; Moschos SJ; Hamid O; Atkins MB; Lewis K; Thomas RP; Glaspy JA; Jang S; Algazi AP; Khushalani NI; Postow MA; Pavlick AC; Ernstoff MS; Reardon DA; Puzanov I; Kudchadkar RR; Tarhini AA; Sumbul A; Rizzo JI; Margolin KA
Neuro Oncol; 2021 Nov; 23(11):1961-1973. PubMed ID: 33880555
[TBL] [Abstract][Full Text] [Related]
46. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
Sussman TA; Li H; Hobbs B; Funchain P; McCrae KR; Khorana AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436486
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
[TBL] [Abstract][Full Text] [Related]
48. Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.
Rosner S; Kwong E; Shoushtari AN; Friedman CF; Betof AS; Brady MS; Coit DG; Callahan MK; Wolchok JD; Chapman PB; Panageas KS; Postow MA
Cancer Med; 2018 Mar; 7(3):690-697. PubMed ID: 29468834
[TBL] [Abstract][Full Text] [Related]
49. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
50. Gastrointestinal complications in patients treated with ipilimumab and nivolumab combination therapy or monotherapy.
Irwin DE; Davis B; Bell JA; Galaznik A; Garcia-Ribas I
J Comp Eff Res; 2019 Jan; 8(2):81-90. PubMed ID: 30547675
[TBL] [Abstract][Full Text] [Related]
51. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
52. Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients.
Amaral T; Kiecker F; Schaefer S; Stege H; Kaehler K; Terheyden P; Gesierich A; Gutzmer R; Haferkamp S; Uttikal J; Berking C; Rafei-Shamsabadi D; Reinhardt L; Meier F; Karoglan A; Posch C; Gambichler T; Pfoehler C; Thoms K; Tietze J; Debus D; Herbst R; Emmert S; Loquai C; Hassel JC; Meiss F; Tueting T; Heinrich V; Eigentler T; Garbe C; Zimmer L;
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221017
[TBL] [Abstract][Full Text] [Related]
53. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Larkin J; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Lao CD; Cowey CL; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hogg D; Hill A; Márquez-Rodas I; Haanen J; Guidoboni M; Maio M; Schöffski P; Carlino MS; Lebbé C; McArthur G; Ascierto PA; Daniels GA; Long GV; Bastholt L; Rizzo JI; Balogh A; Moshyk A; Hodi FS; Wolchok JD
N Engl J Med; 2019 Oct; 381(16):1535-1546. PubMed ID: 31562797
[TBL] [Abstract][Full Text] [Related]
54. Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers.
Klein O; Kee D; Markman B; Michael M; Underhill C; Carlino MS; Jackett L; Lum C; Scott C; Nagrial A; Behren A; So JY; Palmer J; Cebon J
Clin Cancer Res; 2020 Sep; 26(17):4454-4459. PubMed ID: 32532787
[TBL] [Abstract][Full Text] [Related]
55. Autoimmune Bell's Palsy Following Immunotherapy For Metastatic Melanoma: A Report of 2 Cases.
Zieman D; Frankel AE
J Immunother; 2019 Oct; 42(8):318-320. PubMed ID: 31318723
[TBL] [Abstract][Full Text] [Related]
56. The efficacy and safety of combined ipilimumab and nivolumab versus ipilimumab in patients with Stage III/IV unresectable melanoma: A systematic review and meta-analysis.
Zhu Y; Cheng H; Zhong M; Hu Y; Li Q; Gao X; Liu S
J Cancer Res Ther; 2021 Dec; 17(7):1679-1688. PubMed ID: 35381739
[TBL] [Abstract][Full Text] [Related]
57. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
D'Angelo SP; Mahoney MR; Van Tine BA; Atkins J; Milhem MM; Jahagirdar BN; Antonescu CR; Horvath E; Tap WD; Schwartz GK; Streicher H
Lancet Oncol; 2018 Mar; 19(3):416-426. PubMed ID: 29370992
[TBL] [Abstract][Full Text] [Related]
58. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
Doki Y; Ajani JA; Kato K; Xu J; Wyrwicz L; Motoyama S; Ogata T; Kawakami H; Hsu CH; Adenis A; El Hajbi F; Di Bartolomeo M; Braghiroli MI; Holtved E; Ostoich SA; Kim HR; Ueno M; Mansoor W; Yang WC; Liu T; Bridgewater J; Makino T; Xynos I; Liu X; Lei M; Kondo K; Patel A; Gricar J; Chau I; Kitagawa Y;
N Engl J Med; 2022 Feb; 386(5):449-462. PubMed ID: 35108470
[TBL] [Abstract][Full Text] [Related]
59. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.
Sznol M; Ferrucci PF; Hogg D; Atkins MB; Wolter P; Guidoboni M; Lebbé C; Kirkwood JM; Schachter J; Daniels GA; Hassel J; Cebon J; Gerritsen W; Atkinson V; Thomas L; McCaffrey J; Power D; Walker D; Bhore R; Jiang J; Hodi FS; Wolchok JD
J Clin Oncol; 2017 Dec; 35(34):3815-3822. PubMed ID: 28915085
[TBL] [Abstract][Full Text] [Related]
60. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
